Manila Times Business
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast on Saturday, June 13 at 9:00 a.m. ET/8:00 a.m. CT to discuss interim six-month results from the Company’s Phase 2 trial evaluating setmelanotide in patients with Prader-Willi syndrome (PWS). David Meeker,
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
The Children’s Place Reports First Quarter 2026 Results
2h ago
India's viral Cockroach Janta Party launches nationwide youth protest campaign
2h ago
The skills people still perform better than AI, according to workplace experts
2h ago
From YouTube to Disney+: Preschool hit 'Gracie's Corner' lands streaming and development deal
2h ago